Gain Therapeutics, Inc.

NasdaqGM:GANX 株式レポート

時価総額：US$70.4m

Gain Therapeutics 将来の成長

Future 基準チェック /06

Gain Therapeuticsは、30.7%と55.9%でそれぞれ年率30.7%で利益と収益が成長すると予測される一方、EPSはgrowで33.3%年率。

主要情報

30.7%

収益成長率

33.26%

EPS成長率

Biotechs 収益成長25.4%
収益成長率55.9%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日13 May 2026

今後の成長に関する最新情報

Recent updates

分析記事 • 15h

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
分析記事 • May 05

3 US Biotechs Developing Parkinson’s Therapies

Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.
新しいナラティブ • Apr 01

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Seeking Alpha • Nov 07

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Summary Gain Therapeutics achieved functional improvement in Parkinson’s patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287’s mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX’s $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions. I reiterate a Strong Buy rating for GANX. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Summary Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation. Read the full article on Seeking Alpha
Seeking Alpha • May 29

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors. Gain Therapeutics is considerably undervalued compared to peers and recent acquisition targets in the neurodegenerative space. Read the full article on Seeking Alpha
Seeking Alpha • Jan 12

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Summary Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is currently in a Phase 1 trial for GBA-1-PD, and Gain will add further preclinical data in February to its already interesting preclinical dataset. Gain's stock has been performing well, and similarities with a recent acquisition of Caraway Therapeutics by Merck may confirm its undervaluation. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Gain Therapeutics appoints CEO

Biotechnology company Gain Therapeutics (NASDAQ:GANX) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight members. Richman will continue to serve as a board member and as a senior advisor. Source: Press Release
Seeking Alpha • Oct 27

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases. The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated either by trial data or major investment. Gain has not yet had an IND accepted by the FDA, but targets include GM1 Gangliosidosis, Parkinson's, and Gaucher Disease. There are areas of high unmet need and competitive fields, but Gain does at least have some promising preclinical data. The $7 per share entry point feels cheap to me, with numerous upcoming catalysts, an experienced management team and Board, and oral availability all plus points.
Seeking Alpha • Aug 19

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with multiple value inflections expected. Management has a track record of creating value through pharma partnerships and exits. Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.

業績と収益の成長予測

NasdaqGM:GANX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028N/A-33N/AN/A2
12/31/2027N/A-36N/AN/A5
12/31/2026N/A-24N/AN/A5
3/31/2026N/A-21-19-19N/A
12/31/2025N/A-20-18-18N/A
9/30/2025N/A-19-17-17N/A
6/30/2025N/A-19-18-18N/A
3/31/2025N/A-21-19-19N/A
12/31/2024N/A-20-19-19N/A
9/30/2024N/A-21-21-21N/A
6/30/2024N/A-22-19-19N/A
3/31/2024N/A-21-18-18N/A
12/31/20230-22-19-19N/A
9/30/20230-22-17-17N/A
6/30/20230-22-17-16N/A
3/31/20230-19-17-16N/A
12/31/20220-18-15-15N/A
9/30/20220-16-15-15N/A
6/30/20220-16-14-14N/A
3/31/20220-15-12-12N/A
12/31/20210-14-12-12N/A
9/30/20210-12-10-10N/A
6/30/20210-8-8-8N/A
3/31/2021N/A-5-5-5N/A
12/31/2020N/A-4-3-3N/A
9/30/2020N/A-3-2-2N/A
12/31/2019N/A-2N/A-2N/A

アナリストによる今後の成長予測

収入対貯蓄率: GANX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GANX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: GANX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GANX来年は収益がないと予測されています。

高い収益成長: GANX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GANXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 16:03
終値2026/05/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Gain Therapeutics, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG
Raghuram SelvarajuH.C. Wainwright & Co.